Lin Willie, Hsuan Yogi Chang-Yo, Su Yu-Chin, Lin Cheng-Hsien, Lin Mao-Tsun, Chen Zi-Hao, Chang Ching-Ping, Lin Kao-Chang
Meridigen Biotech Co., Ltd., Taipei, Taiwan.
Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Oncotarget. 2017 Dec 15;9(2):1992-2001. doi: 10.18632/oncotarget.23324. eCollection 2018 Jan 5.
CD34 is a transmembrane phosphoglycoprotein used to selectively enrich bone marrow in hematopoietic stem cells for transplantation. Treating rats with CD34 cells derived from human umbilical cord blood before or after heat stroke has been shown to promote survival. We investigated whether CD34 human placenta-derived stem cells (PDMSCs) could improve survival following heat stroke in rats. Rats were subjected to heat stress (42°C for 98 min) to induce heat stroke. Intravenous administration of PDMSCs 1 day before or immediately after the onset of heat stroke improved survival by 60% and 20%, respectively. Pre-treatment with CD34 PDMSCs protected against heat stroke injury more effectively than that treatment after injury. PDMSCs treatment attenuated cerebrovascular dysfunction, the inflammatory response, and lipid peroxidation. These data suggest human PDMSCs protect against heat stroke injury in rats. Moreover, these effects do not require the presence of CD34 cells.
CD34是一种跨膜磷酸糖蛋白，用于在造血干细胞移植中选择性富集骨髓。研究表明，在中暑前后用源自人脐带血的CD34细胞治疗大鼠可提高存活率。我们研究了源自人胎盘的CD34干细胞（PDMSCs）是否能提高大鼠中暑后的存活率。对大鼠施加热应激（42°C，持续98分钟）以诱导中暑。在中暑发作前1天或发作后立即静脉注射PDMSCs，存活率分别提高了60%和20%。用CD34 PDMSCs进行预处理比损伤后治疗更有效地预防中暑损伤。PDMSCs治疗减轻了脑血管功能障碍、炎症反应和脂质过氧化。这些数据表明，人PDMSCs可保护大鼠免受中暑损伤。此外，这些作用不需要CD34细胞的存在。
